Annamaria Balogh
Overview
Explore the profile of Annamaria Balogh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
46
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Noe S, Jonsson-Oldenbuettel C, Jaeger H, Schoenitzer V, Balogh A, Wolf E, et al.
Curr HIV Res
. 2022 Mar;
20(3):200-203.
PMID: 35319375
Background: Small experimental studies suggest that PTH-secretion following hypocalcemia might be blunted in people living with HIV. Objective: The aim of the study was to estimate the frequency of inadequately...
2.
Monin M, Kummerle T, Schneider J, Cordes C, Heiken H, Stellbrink H, et al.
HIV Res Clin Pract
. 2022 Mar;
23(1):15-21.
PMID: 35234092
Switching from a three-drug regimen (3DR: boosted darunavir [bDRV] and two nucleoside reverse transcriptase inhibitors [NRTIs]) to a two-drug regimen (2DR: bDRV and dolutegravir [DTG]) demonstrated non-inferiority with regard to...
3.
Wolf E, Boesecke C, Balogh A, Bidner H, Cordes C, Heiken H, et al.
AIDS Res Ther
. 2021 Sep;
18(1):58.
PMID: 34496848
Objective: The DUALIS study showed that switching to boosted darunavir (bDRV) plus dolutegravir (DTG; 2DR) was non-inferior to continuous bDRV plus 2 nucleoside/nucleotide reverse-transcriptase inhibitors (NRTIs; 3DR) in treatment-experienced virologically...
4.
Postel N, Wolf E, Balogh A, Obermeier M, Degen O, Mayr C, et al.
Exp Clin Endocrinol Diabetes
. 2021 Jan;
129(11):798-802.
PMID: 33477181
Introduction: HIV infection has become a chronic, well-treatable disease and the focus of caretakers has shifted to diagnosis and treatment of comorbidities. Hypogonadism in elderly men with HIV might be...
5.
Weidlich S, Boesecke C, Schneider J, Klinker H, Zink A, Balogh A, et al.
J Antimicrob Chemother
. 2020 Jul;
75(10):3082-3084.
PMID: 32634214
No abstract available.
6.
Boretzki J, Wolf E, Wiese C, Noe S, Balogh A, Meurer A, et al.
Patient Prefer Adherence
. 2017 Nov;
11:1897-1906.
PMID: 29184394
Background: Reasons for and frequency of nonadherence to antiretroviral therapy (ART) may have changed due to pharmacological improvements. In addition, the importance of known non-pharmacologic reasons for nonadherence is unclear....
7.
Oldenbuettel C, Wolf E, Ritter A, Noe S, Heldwein S, Pascucci R, et al.
Antivir Ther
. 2016 Sep;
22(2):169-172.
PMID: 27588613
Background: The potential toxicity of long-term antiretroviral therapy (ART) requires ongoing investigation of novel strategies for treatment of HIV-infected patients. Monotherapy with the integrase inhibitor (INSTI) dolutegravir (DTG) may offer...
8.
Spinner C, Kern K, Zink A, Wolf E, Balogh A, Noe S, et al.
Antivir Ther
. 2016 Apr;
21(7):627-631.
PMID: 27050630
Background: Insulin resistance (IR) was one of the first reported complications in HIV-positive patients who were receiving antiretroviral therapy (ART). However, the metabolic effects of newer fixed-dose ART combinations are...